Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4 þ Foxp3 þ T cells
Lenalidomide has demonstrated significant clinical activity in patients with newly diagnosed and relapsed multiple myeloma (MM). 1 Its actions are believed to be mediated by apoptosis, anti-angiogenic and anti-proliferative activity; inhibition of cytokine production; and stimulation of T-cell and natural killer (NK) cell immunity and cytotoxicity. 2 These immunostimulatory properties suggest that lenalidomide especially can be very effective after allogeneic stem cell transplantation (allo-SCT) or donor lymphocyte infusions (DLI) by enhancing the donor T-cell-or NK cell-mediated graft-versus-myeloma effect.
To explore this, lenalidomide was administered to 16 MM patients who relapsed after allo-SCT. To benefit optimal from the immunostimulatory effects, dexamethasone was not routinely given. In addition, we analyzed peripheral blood collected from eight patients before, during and after the first cycle of treatment to evaluate the influence of lenalidomide on the cellular immune responses.
A total of 16 MM patients (11 males and 5 females; median age: 58.5 years (range: 43-67) who relapsed after an allo-SCT started lenalidomide treatment between September 2005 and December 2007 (Table 1) . Three patients started within 3 months after the allo-SCT, 15 patients had received several other treatments for multiple relapses after allo-SCT, including thalidomide (given to 14 patients; 10 became refractory) and bortezomib (given to 11 patients; 7 became refractory) ( Table 1) . Eight patients switched to lenalidomide as relapse treatment due to peripheral polyneuropathy. Two patients had been treated with lenalidomide before allo-SCT and reached a partial remission after one and three cycles, respectively, and then proceeded to allo-SCT. Eleven patients had received DLI(s); of these, seven patients started with lenalidomide within 3 months after their DLI owing to progressive disease. All patients except three (Table 1 , patient nos. 2, 10 and 13) had experienced episodes of graft-versus-host disease (GvHD). At the start of therapy, three patients had symptoms of chronic GvHD. One patient had grade 2 acute GvHD of the skin. Other GvHD episodes were in remission. Lenalidomide (Celgene International Sarl, Neuchatel, Switzerland) was administered for 21 days at 25 mg/day, followed by 1 week rest for a maximum of six courses. Lenalidomide was combined with pulsed dexamethasone (40 mg/day, days 1-4 and 15-18) after two cycles in five patients, and from the start in three patients (Table 1 , patient nos. 9-16). Dexamethasone at the starting of the treatment.
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Response and progression were assessed according to the European Group for Blood and Marrow Transplantation (EMBT) criteria with the addition of very good partial relapse, indicating a response greater than 90%. 3 Response rates are based on the disease measurements within 3 weeks before starting treatment. GvHD was graded according to the Glucksberg criteria. 4 Heparinized blood samples were collected from eight patients before, during (between days 7 and 14) and after the first cycle of treatment. Just prior to lenalidomide treatment, only patient no. 1 had received thalidomide, another immunomodulatory drug. All patients provided written informed consent for the use of their blood for immunomonitoring purposes.
Peripheral blood mononuclear cells were isolated and cryopreserved in liquid nitrogen until use. FITC-, Per-CP-, PEor APC-conjugated antibodies against CD3, CD4, CD8, CD25, CD56, CD40L (Becton Dickinson, San Jose, CA, USA), Va24, Vb11 (Immunotech, Marseille, France) were used in threeor four-color flow cytometry to determine the frequency of different cell subsets in peripheral blood mononuclear cells. FOXP3 þ cells were detected using an intracellular human FOXP3 staining kit (eBioscience, San Diego, CA, USA). Prior to intracellular staining of FOXP3, cells were surface labeled with fluorescent antibodies against CD4 and CD25. Interferon-g (IFN-g)-secreting cells were detected by a cytokine secretion capture assay (Miltenyi Biotec, Bergisch Gladbach, Germany) after the stimulation of peripheral blood mononuclear cells with anti-CD3/anti-CD28 beads (Dynalbeads, Invitrogen, Carlsbad, CA, USA) for 24 h. Cells were also stained with fluorescent antibodies against CD4 and CD14 to determine the phenotype of IFN-g-secreting cells. Data were analyzed by FACScalibur (Becton Dickinson, San Jose, CA, USA) flow cytometer and by CellQuest software. The Friedman test was used to determine the statistical significance of the relative differences in the frequencies of different T-cell subsets before, during and after treatment. P-values o0.05 were considered significant.
A total of 13 patients started their treatment with lenalidomide only (Table 1 , patient nos. 1-13). Six of these patients (patient nos. 1-6) responded including three with a complete remission. One patient responded with a minimal response only, he died shortly after starting treatment. Patient nos. 9-13 received a combination of lenalidomide and dexamethasone after the second lenalidomide cycle because of insufficient response after two cycles. Four of these five patients responded to the combination therapy. In three patients (patient nos. 14-16), lenalidomide was combined with dexamethasone from the start because of a very rapidly progressing disease. All of these patients responded.
Maximal response to lenalidomide was observed after a median of two cycles (range: 1-5). After a median follow up of 396 days (range: 37-682), the median progression-free survival was 328 days (range: 37-516) and the median overall survival was 395 days (range: 37-682). Two patients (patient nos. 7 and 8) died from infections associated with GvHD and two patients (patient nos. 4 and 6) died from progressive disease.
In summary, 46% (6/13) of the patients responded to lenalidomide alone, and most poor responders benefited from the combination with dexamethasone, resulting in an overall response rate of 87.5%. This high response rate is remarkable for relapsed or refractory MM patients and may be due to the direct antitumor effects of these drugs. However, the clinical responses observed with lenalidomide alone are probably also accountable to its immunostimulatory effects. Supporting this idea, 5 out of 13 patients starting with lenalidomide alone developed acute GvHD between 2 and 13 days after the start of treatment. The occurrence of acute GvHD was a good predictive factor for clinical response: four out of these five GvHD patients developed a good response (the 5th GvHD patient lived too short to determine the antitumor response). Only three patients responded without developing GvHD. Interestingly, all five GvHD patients had received an allo-SCT or DLI shortly before (5 months or earlier) lenalidomide treatment, whereas the three responders without GvHD had received the allo-SCT or DLI at least 1.5 years before. Patients who started lenalidomide with dexamethasone did not develop GvHD, regardless of the interval time.
To evaluate the immunomodulatory effects, blood samples were taken from eight patients during the first treatment cycle. None of them used dexamethasone at the time of blood sampling. In the peripheral blood, low frequencies of dendritic cells and NK T cells were detected and appeared stable (data not shown). Alterations in the frequencies of CD3 À CD56 þ NK cells were not consistent (Figure 1a) . However, the frequencies of CD4 þ and CD8 þ T cells declined during treatment and recovered thereafter (Po0.05) (Figures 1b and c) . In contrast, the frequencies of CD4 þ FOXP3 þ cells showed a significant increase in seven of eight patients during lenalidomide administration and later declined (Po0.001) (Figures 1d and  e) . FOXP3 is considered a specific marker for regulatory T cells (Tregs). However, activated effector T cells may also show temporary expression of FOXP3. 5 To evaluate this, we determined the frequencies of IFN-g-secreting CD4
þ T cells and sought a correlation between FOXP3 þ and IFN-g þ T cells (Figure 1f ). Unlike FOXP3 þ cells, the frequencies of IFN-g þ T cells remained stable or tended to decline during treatment. In fact, the FOXP3 þ and the IFN-g þ T cells appeared to show an inverse relation, as suggested by the significant increase in the FOXP3
þ -to-IFN-g þ T cell ratios during treatment (P ¼ 0.008) (Figure 1g ). Such a significant relation was not found between FOXP3
þ and NK cells (Figure 1h ). Taken together, these results most probably reflect the increase of Tregs and their downregulatory effects on (IFN-g-secreting) CD4 þ and CD8 þ T cells. Tregs have been associated with disease progression in MM patients and may also downregulate GvHD after allo-SCT. 6, 7 However, in our small cohort, the impact of the increase in Tregs on the clinical outcome is not clear. Probably due to the small number of analyzed patients, we did not find any association between FOXP3 þ T cells, GvHD and clinical responses. The development of severe acute GvHD, despite high levels of circulating FOXP3 þ cells in a number of patients, indicates that Tregs may not always be capable of neutralizing the immunostimulatory effects of lenalidomide. On the other hand, the fact that GvHD did not develop in other patients, and that the symptoms of chronic GvHD improved in two patients, could be interpreted as an effective compensation of the immunostimulatory effects of lenalidomide by Tregs. Nonetheless, as several other explanations are also possible, larger studies are necessary to unravel the precise mechanism and consequences of the increase of FOXP3 þ T cells during lenalidomide treatment.
In conclusion, our study shows, for the first time, that lenalidomide therapy in relapsed MM patients after allo-SCT is very effective with a response rate of 87.5%. When given as monotherapy within months after allo-SCT or DLI, it can elicit a very rapid immune response causing severe acute GvHD. This supports the in vitro data on the immunostimulatory capacity of lenalidomide. The exact role of the novel observation of Table 1 ). P-values were calculated using the Friedman test. FACS, fluorescence-activated cell sorting; GvHD, graft-versus-host disease.
